Murdo Gordon appointed Executive Vice President and Chief Commercial Officer, BMS
He will lead the company's Worldwide Markets in addition to a new Worldwide Commercialization team.
Bristol-Myers Squibb (BMS) has announced that Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly created position, effective 21 June 2016. Gordon will be responsible for leading the execution of commercial strategy across geographies. In this role, he will lead the company's Worldwide Markets in addition to a new Worldwide Commercialization team. Gordon will continue to report to Giovanni Caforio, CEO, and remain a member of his Leadership Team. Gordon most recently co-led the commercial organization as Head of Worldwide Markets.
“Murdo has demonstrated tremendous success driving commercial excellence at BMS, and built strong relationships with our markets across the world,” said Caforio. “Murdo has made significant contributions to our success in immuno-oncology and Eliquis, and I am confident his leadership will help drive continued growth and deliver our medicines to more patients faster.”
Gordon joined BMS in 1989 and spent the first 14 years at the company in Canada where he held positions of increasing responsibility in sales and marketing. Gordon moved into the company’s US operations in 2003 where he held senior commercial leadership positions in cardiovascular, neuroscience and market access. He led strategy and commercial operations as senior vice president for US oncology and immunoscience from 2011 to 2013, and served as president, US from 2013 to 2015. Murdo is a member of the Board of Directors of RWJBarnabas Health and received a BSc in Cell and Molecular Biology from Concordia University, Montreal, and also attended the General Management Program, CEDEP at INSEAD, Fontainebleau, France.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.